Sign inJoin waitlistJoin the waitlist

Megan Daly

Professor and Chair — Radiation Oncology · University of California

Credentials: · · ·

History

University of California
Present
University of California
Present
University of California Davis Health
Present

Radiation Oncology
Stanford Health Care
2007–2011
Preliminary or Transitional Year
2006–2007
Stanford University School of Medicine
2002–2006

Research

Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial
Journal of Clinical Oncology · 2019 · 470 citations
Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline
Practical Radiation Oncology · 2017 · Last of 18 authors · 380 citations
Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study
The Lancet Oncology · 2017 · Last of 18 authors · 273 citations

Gregory Farwell
14 papers
AC
Allen Chen
13 papers
Daniel Chang
10 papers
KK
Karen Kelly
10 papers
CS
Charles Simone
9 papers
Michael Kaplan
9 papers
Arta Monjazeb
8 papers · 1 as a resident
Billy Loo
8 papers
James Murphy
8 papers · 7 as a resident
Quang Luu
8 papers
Clifford Robinson
7 papers
Gregory Videtic
7 papers

Clinical trials

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2020–2027
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
Principal investigator · Active not recruiting · Phase 1, Phase 2
Megan Daly, MD
2019–2026
UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
Principal investigator · Completed · Phase 1, Phase 2
University of California, Davis
2018–2020
UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients
Principal investigator · Completed · Early phase 1
Megan Daly, MD
2017–2020